Adjuvant Therapy in High-Risk, Node-Negative Melanoma

Merrick I. Ross

Adjuvant Therapy in High-Risk, Node-Negative Melanoma

Surgical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	445-448
Number of pages	4
Journal	Clinical Advances in Hematology and Oncology
Volume	21
Issue number	8
State	Published - Aug 2023

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{c9ae52358b8148c4acb007719a159974,

title = "Adjuvant Therapy in High-Risk, Node-Negative Melanoma",

author = "Ross, {Merrick I.}",

note = "Funding Information: Dr Ross is a member of the global advisory board of Merck, is a paid speaker for Merck and Amgen, and has received a research grant from Amgen.",

year = "2023",

month = aug,

language = "English (US)",

volume = "21",

pages = "445--448",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "8",

}

TY - JOUR

T1 - Adjuvant Therapy in High-Risk, Node-Negative Melanoma

AU - Ross, Merrick I.

N1 - Funding Information: Dr Ross is a member of the global advisory board of Merck, is a paid speaker for Merck and Amgen, and has received a research grant from Amgen.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85166124089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166124089&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 37530620

AN - SCOPUS:85166124089

SN - 1543-0790

VL - 21

SP - 445

EP - 448

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 8

ER -

Adjuvant Therapy in High-Risk, Node-Negative Melanoma

ASJC Scopus subject areas

Other files and links

Cite this